Subretinal Macugen® for Neovascular Age-Related Macular Degeneration
Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of pegaptanib (Macugen®) for neovascular
(exudative) age-related macular degeneration (AMD) when the first dose is administered to the
submacular space instead of vitreous body in cases when previous state-of-the-art treatment
for the AMD was deemed ineffective.